EMEA-001175-PIP01-11-M04
Key facts
Invented name |
Eperzan
|
Active substance |
Albiglutide
|
Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
Decision number |
P/0272/2016
|
PIP number |
EMEA-001175-PIP01-11-M04
|
Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Glaxo Group Limited
E-mail: eu.paediatrics-plans@gsk.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|